CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CORPORATE PRESENTATION SEPTEMBER 2021
DISCLAIMER IMPORTANT NOTICE. This presentation (“Presentation”) is an overview of Lobe Sciences Ltd. (the “Company”) and is for information purposes only and should not be relied on for the purposes of making an investment decision. This Presentation does not, and it is not intended to, provide any financial, legal, accounting, or tax advice, and must not be relied upon by you in that regard. The Presentation should not be used, or relied upon by you, as a substitute for your independent research or consultation with your own financial, legal or tax advisors. There are significant risks associated with an investment in the Company. The information contained in this Presentation has been provided by the Company or obtained from publicly available sources or third-party sources and has not been independently verified. While the Company has not verified third party information, nevertheless, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or any opinions contained herein and nothing in this Presentation is, or shall be relied upon as, a promise or representation by the Company. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s financial or trading position or prospects. The information and any opinions presented herein are provided as at the date of this document based on general information gathered at the time of writing and are subject to change without notice. None of the Company nor any of its affiliates, directors, officers, employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of these materials or its contents or otherwise arising in connection with this Presentation. This Presentation and any related oral presentations do not constitute an offer or invitation to subscribe for, purchase or otherwise acquire any securities or other debt instruments of the Company and nothing contained herein or its Presentation shall form the basis of any contract or commitment whatsoever, nor does it constitute a recommendation regarding the securities of the Company. All dollar amounts stated in this Presentation are expressed in United States currency, except where otherwise indicated. FORWARD-LOOKING INFORMATION & FORWARD-LOOKING STATEMENTS CAUTIONARY STATEMENT Certain statements in this Presentation may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of applicable securities laws. This Presentation contains forward-looking information relating to the Company’s future outlook and anticipated events or results and may include statements regarding its financial results, future capital expenditures, cash flow, investment payouts, valuations, plans, objectives, potential synergies, industry trends, growth opportunities and other matters (“forward-looking statements”). These statements relate to future events or future performance. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “budget”, “plan”, “estimate”, “expect”, “forecast”, “may”, “might” “will”, “project”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe” , “likely”, and similar expressions or variations (including negative variations) of such words or phrases. Forward-looking statements are based on the opinions, assumptions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information or forward-looking statements. These risks, uncertainties and other factors include, but are not limited to risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business a acquisition strategies, and the other risks common for a business such as the Company’s. The foregoing factors are not intended to be exhaustive. Although the company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those. The Company cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements. The forward- looking statements contained in this Presentation are expressly qualified by this cautionary statement. The Company undertakes no obligation to update or revise publicly any forward-looking statements except as required by applicable securities legislation. The forward-looking statements made herein relate only to events or information as of the date on which the statements are made. The reader is cautioned not to place undue reliance on forward-looking statements. This presentation contains information regarding the past performance of a company, including but not limited to the financial information of this Presentation. Recipients of this Presentation should be aware that that past performance should not be relied upon as being indicative of future performance. Lobe Sciences Ltd. is publicly traded on the Canadian Stock Exchange under the ticker LOBE and more information on Lobe Sciences can be found on the CSE website at https://thecse.com/en/listings/life-sciences/lobe-sciences-ltd Not for public distribution and not for release or distribution outside Canada Importantly, the distribution of this Presentation in other jurisdictions outside Canada may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.
WHO WE ARE
Lobe Sciences is a life sciences company focused on Vision:
psychedelic medicines. The Company is engaged in drug Developing and delivering solutions to
research and development using psychedelic compounds improve the human condition.
and the development of innovative devices and delivery
mechanisms to improve mental health and wellness.
The Company plans to develop transformational
medicines and devices as we build a growing portfolio of Mission:
intellectual property to support wellness and improve To identify and develop transformative
mental health. new medicines, compounds and devices to
improve health and provide new pathways
We focus on clinical development of devices and medicines to medicines.
to treat specific medical conditions and brain traumas.
Additionally, generating ongoing cash flow from licensing
and other agreements.
INTRODUCTION TO PSYCHEDELICS
Psilocybin DMT LSD MDMA
Psychedelic drugs exert psychoactive effects on users:
- Psilocybin
- Dimethyltryptamine (DMT)
- Lysergic acid diethylamide (LSD)
- Methylenedioxymethamphetamine (MDMA)
Serotonin regulates mood, happiness, and anxiety.
Photos by ACS.org Psychedelics activate serotonin receptors in the brain—5HT2A.
HISTORY OF PSYCHEDELICS PSILOCYBIN REFORM IN THE USA
~5000 BCE
Frescos of mushroom- ~ 4000 BCE
holding shamans were In a cave near the town of May 2019
depicted in caves on the Villar del Humo in Spain, Denver, CO becomes the
Tassili plateau of June 2019
the Selva Pascuala mural first city to decriminalize
Southeastern Algeria. psilocybin Oakland, CA follows
depicts what appear to be
suite and decriminalizes
psilocybin mushrooms.
~1500 BCE January 2020 psilocybin
These paintings provide
Archaeological
the earliest evidence of Santa Cruz, CA
“mushroom stones”
the use of psychedelic decriminalizes September 2020
indicate that a
mushrooms in Europe. psilocybin
sophisticated mushroom Ann Arbor, MI
cult existed in Guatemala. 1000 BCE decriminalizes psilocybin
Statues in Mexico depicted November 2020
1799: October
Psilocybe mexicana with god-
In London, the first like figures emerging from it, Oregon to become
psychedelic mushroom indicating religious use. the first state to June 2021
experience was allow the use of
California Senate
documented in a scholarly 1904: August psilocybin in
Passage of
journal by Dr. Everard therapy and votes
American mycologist Franklin Groundbreaking
to decriminalize
Brande. The mushrooms Sumner Earle was the first Psychedelic Reform Bill
psilocybin
were determined to be person to collect and identify
Psilocybe semilanceata. Psilocybe cubensis in Cuba.
1. https://psychedelictimes.com/psychedelic-timeline/?fbclid=IwAR1Abz3BgbYlyd_29411QT11Vom7EgSO5IG9WSxXQU_xKJGMifeXM0h8C-Q
2. https://psychedelicinvest.com/mapping-psilocybin-reform/
NEAR TERM FOCUS
Treatments for mTBI and PTSD with NAC and Psychedelics
Current preclinical study ongoing with
University of Miami for the treatment of
PTSD and/or traumatic brain injury with
PTSD
Delivery Devices for Efficient Drug Delivery
Engineering design and development for Nasal
Mist Delivery Device has begun
THE MARKET OPPORTUNITY - PTSD
10% 8M $16T 20% 7% 40%
Approximately the Number of adults Estimated global Percentage of combat Percentage of Approximately the
percentage of people suffering from PTSD each expenditure on mental veterans suffering from adolescents between percentage of people
suffering from PTSD year. health by 2030 (in USD). PTSD. ages of 17-18 suffering impacted by mTBI that
during their lifetime. from PTSD. suffer from PTSD.
THE MARKET OPPORTUNITY - TBI
54% ~69M $2.9B 2:1 ~5.3M
The increase of TBI- Value of the global Male to female ratio. The CDC's National
Individuals worldwide
related emergency traumatic brain injury Center for Injury
are estimated to sustain
department visits from assessment and Prevention and Control
a TBI each year.
2006-2014 in the United management devices estimates that 5.3 million
States. market in 2020. U.S. citizens (2 percent of
the population) are living
with disability as a result
TBI Sources: https://www.cdc.gov/traumaticbraininjury/get_the_facts.html
of a traumatic brain
https://thejns.org/view/journals/j-neurosurg/130/4/article-p1080.xml injury.
https://www.grandviewresearch.com/industry-analysis/traumatic-brain-injuries-tbi-assessment-management-devices-market PTSD Sources: https://www.therecoveryvillage.com/mental-health/ptsd/related/ptsd-statistics/#gref
https://www.ncbi.nlm.nih.gov/books/NBK459300/ https://www.reuters.com/article/us-health-mental-global/mental-health-crisis-could-cost-the-world-16-trillion-by-2030-idUSKCN1MJ2QN
https://www.cdc.gov/traumaticbraininjury/pdf/TBI_in_the_US.pdf https://www.psychiatrictimes.com/view/post-covid-stress-disorder-emerging-consequence-global-pandemic
MTBI AND PTSD
The recommended concussion treatment from the Center of Disease Control:
Discuss discharge instructions with patients and give them a discharge instruction sheet to
take home and share with their family and/or caregiver. Be sure to:
• Alert patients to look for post concussive symptoms (physical, cognitive,
emotional, and sleep) since onset of symptoms may not occur until days after the
initial injury.
• Instruct patients on what to expect, what to watch for, and when it is important to
return immediately to the emergency department.
• Emphasize that getting plenty of rest and sleep is very important after a
concussion, as it helps the brain to heal. Patients should gradually return to their
usual routine only after they start to feel better.
There is no standard medicine recommended for treatment of mTBI.
Recent studies have proven the efficacy of treating mTBI and
PTSD with NAC
https://www.cdc.gov/traumaticbraininjury/pdf/TBI_Patient_Instructions-a.pdf
https://clinicaltrials.gov/ct2/show/NCT02499029
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553161/
PSYCHEDELICS AND NAC
Psychedelics Defined: Psychedelics (serotonergic hallucinogens)
are powerful psychoactive substances that alter perception and
mood and affect numerous cognitive processes. They are
generally considered physiologically safe and do not lead to
dependence or addiction.(1)
Some Common Psychedelic Drugs:
LSD –Lysergic Acid Diethylemide
DMT - Dimethyltryptamine
Psilocin/Psilocybin – Magic Mushrooms
MDMA (Ecstasy) - 3,4-methylenedioxy-methamphetamine
Mescaline/Peyote
Psilocybin Mushrooms
N-acetylcysteine (NAC) is a dietary supplement derived
from the amino acid L-cysteine. It is used as an antidote for
acetaminophen overdose. As an antioxidant, it is thought
to reduce DNA damage. NAC is also marketed for its liver-
protective properties and to support healthy immune
functioning.(2)
NAC has been used in multiple studies to
treat mild Traumatic Brain Injuries. (mTBI)(3)
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/
2. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/n-acetylcysteine
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989181/
SERATONIN RECEPTOR ACTIVATION
The 5-HT2A is a G-protein-coupled receptor,
commonly found in serotonin-rich areas of
the brain, which is thought to manifest
psychedelics’ effects (Kyzar et al. ,2017).
Activation of this receptor results in the
increased expression of key genes involved
in creating new synapses in the brain.
(Nichols & Sanders-Bush, 2002).
This could influence the plasticity of neurons
after a single dosage, establishing new long-
term connections.
Figure adapted from Lowe et al., 2021“RESET” BRAIN ACTIVITY PATTERNS
Psychedelics may disrupt and rewire existing PLACEBO PSILOCYBIN
communication networks within the brain to
create new, short-lived and persisting
connectivity between brain regions, not
normally associated.
Neuroimaging psilocybin, ayahuasca, and
LSD studies show decreases in older,
established connections between brain
areas, and increases new activity that
correlates with positive subjective reports in
brain function*.
Figure adapted from Bullmore and Sporns, 2009
One researcher calls this phenomenon as
the brain’s “reset” button.(Carhart-Harris et
al., 2017) *Bullmore & Sporns, 2009; Carhart-Harris et al.,2012; Carhart-Harris et al., 2017RESEARCH FOCUS TBI
Research on psychedelics and Traumatic Brain
Injury (TBI) is limited.
There are investigations in rodent models that
describe the promising effects of psychedelics,
particularly MDMA on TBI.
Researchers found mild TBI preceded by one low
dose was neuroprotective. It prevented decreases
of key neuronal markers after injury, and the
treated mice showed cognitive improvements.
(Edut et al., 2011; Edut et al., 2014)
There are no noted studies or clinical trials related
to TBI and the classic psychedelics.
LOBE SCIENCES AND THE UNIVERSITY OF MIAMI
DATA ANALYSIS UPCOMING
Photo by BrainlineANTI-INFLAMMATORY MECHANISMS Research links pathological inflammation and chronic diseases. (Zhong & Shi, 2019) Psychedelics including LSD, have been shown to have anti-inflammatory effects, by inhibiting a key proinflammatory protein (TNF). Additionally, psychedelics may reduce inflammation- related gene expression (including IL-6) after receptor activation. Psychedelics may have a novel mechanism, reducing inflammation through intracellular mechanisms instead of reducing TNF from circulation.
UNIVERSITY OF MIAMI
PRECLINICAL STUDIES
Early in 2021 The company launched preclinical research studies using psilocybin and N-
Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injury/concussion (“mTBI”) with
post-traumatic stress disorder (“PTSD”)
• The study is in collaboration with a multidisciplinary team of scientists and physicians at the
University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D.,
professor of otolaryngology and neurological surgery.
• NAC has been shown to be safe and efficacious in a phase I human clinical study in treating
military personnel who had suffered mTBI.
• The initial research focus is to demonstrate the safety and efficacy of the combination of
psilocybin and NAC using broadly accepted rodent models.
• The research team at the Miller School of Medicine has conducted prior studies involving NAC
with mTBI and has a license from the United States Drug Enforcement Administration to
conduct research using Schedule I controlled substances, which includes psilocybin.
• Final results are expected in Q4 2021.Preclinical Data: Light/Dark Box Experiment A light dark emergence task is performed by placing rats in a specially designed box/chamber that has a dark and lighted side Rats naturally seek the lighted side Rats with stress or injury tend not be as aggressive at seeking the lighted side
Light Dark Box Results Rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P < 0.000005) than the rodents treated with monotherapy with psilocybin, NAC or placebo.
INTELLECTUAL PROPERTY
Microdosed
Applications and Medical Devices
Compounds
Lobe Sciences Patents Pending:
• Psilocybin combined with NAC for the • Nasal Mist Transducer Device
treatment of mTBI and PTSD and other for delivery of medicines
conditions directly to the Olfactory Bulb
• MDMA combined with NAC for the • Virtual Reality Headset
treatment of mTBI and PTSD and other combined with the Nasal
conditions Mist Device
• Addition of compounds to create
memory odor imprint pairingCOLLABERATIONS
JOINT VENTURE
WITH VPI
Development of Krysalis(TM) Therapeutic Pod to Deliver Headset-free Virtual Experience with
Biometric Monitoring with Virtual Psychedelics:
• Partnered with industry-leading pioneers, including Hollywood director Brett Leonard and
researcher and USC professor Dr. Skip Rizzo, with respect to the joint design, development
and commercialization of a new psychedelic/virtual experience ("VX") pod.
• The Pod will be designed to be powered by a custom tech stack incorporating advanced
display technology and state-of-the-art bio-monitoring with the goal of improving
psychedelic therapy by optimizing set, setting and the overall experience for clinical and
other uses.
• The KrysalisTM Pod will be designed as a headset-free, virtual experience that uses multi-
sensory stimulation to create an application that can offer treatment options for cognitive,
psychological, motor and functional impairments across a wide range of clinical health
conditions.VITAMIND
AQUISITION
• Addition of consumer packaged goods ("CPG") line of functional mushroom products further
expands Lobe's operations and reach across the psychedelic space.
• Vitamind is a brand of non-psychedelic functional mushroom products that includes three
product lines which are specifically focused on boosting immune response and increasing
mental clarity.
• The Vitamind line of products are adaptogenic functional mushroom extract blends, which are
specifically designed to promote wellness, including supporting immune response, and mental
clarity, including improving memory function and reducing anxiety.
• Products include a blend of reishi, cordyceps, lion's mane, turkey tail, mesima, maitake,
bacopa and/or shitake mushrooms.
• The products consist of multiple delivery forms, including capsules, tea bags and
powder, allowing for ease of consumption and convenience, catering to consumer
preferences.• The joint venture gives Lobe the potential to provide cGMP grade psilocybin for the use in
clinical studies it plans to initiate in the future.
• Core One Labs will develop and manage the cGMP production and delivery of biosynthetic
psilocybin.
• The device includes a nasal delivery system for administration of pharmaceutical agents such as
a psilocybin-derived agent preselected dosages.
• Successful completion of phase one development of the device.
• A test platform was constructed and used to quantify key characteristics of the actuator, atomizer, and
control system.
• The testbed was also used to refine the mist volume, quality, and spray pattern.
• The results reflect a clear path for delivering precise doses of drugs to the upper region of the nasal
cavity.COWLITZ DIVESTITURE
On March 8, 2021 the company completed the sale of Washington-based Cowlitz County
Cannabis Cultivation Inc. to Ionic Brands Corp.
• Strengthened Lobe's balance sheet with C$1.75 million cash on closing
• Lobe Sciences received 100,406,701 series E non-voting preferred shares of CNSX:IONC which
convert on a one-to-one basis and carry an annual dividend of 13% for a period of two years
• Lobe Sciences also received 4,000,000 five year C$0.30 Ionic Brand warrants
IONIC BRANDS is a national cannabis
holdings company based in
Washington, led by a team of
successful entrepreneurs. The
company is focused on building a
multi-state consumer-focused
cannabis concentrate brand portfolio
focusing on the premium and luxury
segments.ROADMAP & TIMELINES 2021 - 2022
2021 2022
Q2 Q3 Q4 Q1 Q2 Q3
UNIVERSITY OF MIAMI PRECLINICAL STUDY In TBI and PTSD
Initiate Testing Final Testing and Analysis Data Report
First In Man Study, Psilocybin & NAC
CRO Selection and Protocol Development and Regulatory Review and Approval
Feasibility Analysis Site Selection First Patient First Dose
Identification of Manufacturing Partner To Support Trials and IND
Evaluate Potential Binding Agreement for cGMP Production of
Partners Product and DMF Clinical Trial Material
File Pre-IND and IND With FDA
Regulatory Analysis Pre IND Meeting File IND
and Plan
Nasal Delivery Device Development
Prototype Development Implement Go To Market Go To Market Design
and Testing Design and Feasibility SelectionOUR TEAM
PHILIP MAGHSOUD
J. YOUNG BRIAN DARIANI
ZASTIKO
CEO & Director Chief Financial Officer Chief Science Officer
Mr. Young has served as a Director and Chief Executive Brian has over 13 years of experience across a variety Prior to leading science and technology efforts at LOBE,
Officer for public companies for the past 20 years where of private and public sector companies in the cannabis, Dariani was President of Focus Pharmaceuticals, Inc.,
has had created significant shareholder value, built agriculture, manufacturing, and utility industries. He where he managed the development and approval of
integrated scientific, manufacturing and commercial has extensive experience in financial reporting and drug products, achieving one FDA approval and
operations, directed successful M&A transactions and was corporate governance, as well as in the capital bringing another to the clinical evaluation stage, then
responsible for generating more the $900M through markets. Previously, Brian was a manager at Ernst & successfully negotiated the sale of the company in
acquisitions and equity financings. Young LLP, where he obtained his CPA, CA designation. February 2003.
JONATHAN LEIGHTON MICHAEL
GILBERT BOCKING PETTER
Executive Chairman Director Director
Jonathan was the founder and CEO at Tassili LifeSciences, Leighton has been working in the capital markets for over Michael is an accomplished leader and entrepreneur in the
Corp., a biotech firm conducting research utilizing 15 years. His primary role has been as an independent psychedelics and cannabis industry, co-founding and acting as a director
Psilocybin. Tassili was successfully acquired by a public corporate development consultant in addition to holding of several companies that successfully completed M&A transactions. He
company in March of 2020. He was also the founder and various directorship positions. Leighton has been holds a Bachelors in Computer Science from London University, is
CEO of Scythian Biosciences, Inc. from December of 2014 particularly focused on financing and structuring a Chartered Engineer and private pilot. Since January 2009, he has been
through May of 2018. Prior to founding Scythian companies. An active investor, he started in the industry the Managing Director of Eyvo eProcurement Solutions, a US-based
Biosciences, from January 2013 to December 2014, Gilbert at Canaccord before moving to the public company side private company that is a leading eProcurement provider in the
was Marketing Officer for Commonwealth Opportunity of the business. SaaS space. Mike was co-founder and director of Eleusian Biosciences
Capital, GP, a hedge fund based in Greenwich, Connecticut. Corp., which the Company acquired in July 2020.OUR TEAM
DR. MARK A. GEYER PHD. CHARLES S. GROB MD. BENJAMIN KELMENDI MD.
Scientific Advisor Scientific Advisor Scientific Advisor
Dr. Geyer is Distinguished Professor of Psychiatry and Charles S. Grob, M.D. is Professor of Psychiatry and Pediatrics at the Benjamin is a psychiatrist and an Associate Professor in the
Neurosciences Emeritus at the University of California San UCLA School of Medicine. He previously held faculty positions at the Department of Psychiatry at the Yale University School of
Diego (UCSD) and directs the Neuropsychopharmacology Johns Hopkins School of Medicine and the University of California at Medicine. His primary clinical expertise is in PTSD, Depression,
Unit of the VISN 22 Veterans Administration Mental Illness Irvine. From 2004-2008 he was the Principal Investigator of the first OCD, and the endocannabinoid system. He is the co-founder of
Research, Clinical, and Education Center. He has published study in several decades to examine the use of a psilocybin treatment the Yale Psychedelic Science Group. He leads a research
over 470 peer-reviewed papers, including many addressing model for patients with advanced-cancer anxiety. He has also program focused on the therapeutic potential of psychedelic
the mechanisms subserving the effects of conducted research into the range of effects of MDMA, in both normal medicines, across a range of psychiatric diagnoses.
psychostimulants, psychedelics, and entactogens. volunteers and in a selected subject population of adult autistics with
severe social anxiety.
ILAN HAYMAN BART OATES GILBERTO JESÚS MENDOZA
Advisor Advisor
Ilan has played a pivotal role in the General Management of Advisor
Bart Oates Esq. is a three-time Superbowl Champion, who graduated Gilberto Jesús Mendoza is currently the President of the World
healthcare businesses including a private cosmetic surgery magna cum laude with a Juris Doctor degree from Seton Hall during
chain and the commercialization of a breakthrough skincare Boxing Association. Mr. Mendoza began his career as a lawyer
his off season. Bart was selected to five Pro Bowls during his NFL and an engineer and has been working with the WBA since
range. He successfully led the development of these products career and to the UPI All-NFC team three times. Bart is now the
from concept through to production commercialization. Most 2015. Mr. Mendoza is the proud creator of "Un Solo Boxeo"
President of the NFL Alumni Association which offers former players a (Only One Boxing), a program that promotes the integration of
recently Ilan oversaw a group of national medical centers. His diverse package of medical, business, and legal services to help keep
career into operations management was triggered by his professional boxing. He also created the Future WBA
them and their families healthy, productive, and connected to their Champion, a project that has given space to thousands of
valuable experience as part of the Risk and Controls Solutions former teammates.
practice at PricewaterhouseCoopers (PwC). boxers in their preparation stage for the Tokyo Olympic Games.FULLY DILUTED SHARE CAPITAL
Number Price Expiry
Issued & Outstanding 219,133,984 (5/21/2021)
Stock Options 15,693,836 $0.08 - $0.35 7/15/2021 – 5/30/2028
Warrants 47,679,544 $0.20 - $0.75 5/15/2021 – 10/2/2023
Performance Warrants 4,655,992 $0.35 5/18/2026(1)
Total Fully Diluted 287,163,356
Market Cap as of 08/30/2021: ~$23M CAD
Public Equities trade on
CSE: LOBE
OTC Pink: GTSIF
1 Subject to earlier expiry provisionsThank You!!
Contact:
Philip Young, CEO
phil@lobesciences.com
(949) 505-2653You can also read
